Product Description
Sorbitol is a type of carbohydrate called a sugar alcohol, or polyol. Sorbitol contains about one-third fewer calories than sugar and is 60 percent as sweet. Sorbitol occurs naturally in a variety of berries and fruits (e.g., apples and blackberries) (Sourced from: https://foodinsight.org/what-is-sorbitol/)
Mechanisms of Action: Osmosis Inducer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Dominican Republic | Egypt | Finland | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Lebanon | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Philippines | Portugal | Romania | Russia | Saudi Arabia | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pharnext
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Spain, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Charcot-Marie-Tooth Disease|Hereditary Sensory Neuropathy Type 1|Hereditary Sensory and Motor Neuropathy|Hyperkalemia|Nerve Compression Syndromes
Phase 1: Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12622001101774 |
ACTRN12622001101774 | P1 |
Recruiting |
Other |
2023-10-11 |
2026-02-15 |
Treatments |
|
NCT04762758 |
PREMIER | P3 |
Active, not recruiting |
Hereditary Sensory and Motor Neuropathy|Charcot-Marie-Tooth Disease|Nerve Compression Syndromes |
2024-04-19 |
2024-04-04 |
Primary Endpoints |
|
NCT05092841 |
TSL-CM-PXT3003-â ¢ | P3 |
Completed |
Nerve Compression Syndromes|Hereditary Sensory and Motor Neuropathy|Hereditary Sensory Neuropathy Type 1|Charcot-Marie-Tooth Disease |
2024-03-18 |
9% |
2025-01-10 |
|
CTR20212173 |
CTR20212173 | P3 |
Recruiting |
Hyperkalemia |
None |
21% |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/03/2026 |
News Article |
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics |
|
01/29/2026 |
News Article |
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension |
|
12/11/2025 |
News Article |
Cycle Pharmaceuticals to Acquire Applied Therapeutics |
|
12/09/2025 |
News Article |
Trends in Clarified Polypropylene (PP) Bottles Market 2025-2035 |